2. PI3K/Akt/mTOR NF-κB Apoptosis
  3. PI3K Akt NF-κB Apoptosis
  4. Tenacissoside H

Tenacissoside H  (Synonyms: Tenacissimoside C)

Cat. No.: HY-N0670 Purity: 99.89%
COA
SDS
Handling Instructions Technical Support

Tenacissoside H (Tenacissimoside C) is a compound found in Caulis Marsdeniae Tenacissimae. Tenacissoside H shows anti-inflammation, anti-tumor and neuroprotective effects. Tenacissoside H inhibits PI3K/Akt and NF-κB signaling pathway. Tenacissoside H inhibits cancer cells proliferation, S phase arrest, and inhibits tumor growyh in mice. Tenacissoside H promotes neurological recovery of ischemia-reperfusion injury in mice by inhibiting inflammation and apoptosis. Tenacissoside H can be used for the research of cancer, inflammation and neurological diseases, such as esophageal cancer and cerebral ischemia.

For research use only. We do not sell to patients.

Tenacissoside H

Tenacissoside H Chemical Structure

CAS No. : 191729-45-0

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Tenacissoside H Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Tenacissoside H

View All PI3K Isoform Specific Products:

View All Isoforms
PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

View All Akt Isoform Specific Products:

View All Isoforms
Akt Akt1 Akt2 Akt3

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Tenacissoside H (Tenacissimoside C) is a compound found in Caulis Marsdeniae Tenacissimae. Tenacissoside H shows anti-inflammation, anti-tumor and neuroprotective effects. Tenacissoside H inhibits PI3K/Akt and NF-κB signaling pathway. Tenacissoside H inhibits cancer cells proliferation, S phase arrest, and inhibits tumor growyh in mice. Tenacissoside H promotes neurological recovery of ischemia-reperfusion injury in mice by inhibiting inflammation and apoptosis. Tenacissoside H can be used for the research of cancer, inflammation and neurological diseases, such as esophageal cancer and cerebral ischemia[1][2].

In Vitro

Tenacissoside H (2-10 mg/mL; 24-48 h) potently inhibits human esophageal carcinoma EC9706 cell proliferation in a time- and dose-dependent manner, with IC50 values of 9.81 mg/mL at 24 h and 6.45 mg/mL at 48 h[1].
Tenacissoside H (10 mg/mL; 24 h) blocks human esophageal carcinoma EC9706 cells from entering the S phase from the G1 phase, significantly reducing the percentage of cells in the S phase to 12.82% relative to the blank control group[1].
Tenacissoside H (10 mg/mL; 1-7 days) downregulates PI3K and NF-κB p65 mRNA expression in human esophageal carcinoma EC9706 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Tenacissoside H Related Antibodies

Cell Proliferation Assay[1]

Cell Line: human esophageal carcinoma EC9706 cells
Concentration: 2, 4, 6, 8, 10 mg/mL
Incubation Time: 24 h; 48 h
Result: Significantly inhibited EC9706 cell proliferation in a time- and dose-dependent manner.
Reduced cell proliferation by 52.65% at 10 mg⋅mL-1 after 24 h incubation.
Reduced cell proliferation by 64.79% at 10 mg⋅mL-1 after 48 h incubation.
Exhibited an IC50 of 9.81 mg/mL for 24 h incubation.
Exhibited an IC50 of 6.45 mg/mL for 48 h incubation.

Cell Cycle Analysis[1]

Cell Line: human esophageal carcinoma EC9706 cells
Concentration: 10 mg/mL
Incubation Time: 24 h
Result: Significantly reduced the percentage of EC9706 cells in the S phase to 12.82%.

Real Time qPCR[1]

Cell Line: human esophageal carcinoma EC9706 cells
Concentration: 10 mg/mL
Incubation Time: 1, 3, 5, 7 day
Result: Reduced PI3K mRNA expression over time, with significant differences relative to the blank control group at day 5 and day 7.
Decreased NF-κB p65 mRNA expression from day 3 onward, with significant differences relative to the blank control group at day 5 and day 7.
In Vivo

Tenacissoside H (100 mg/kg; i.p.; twice weekly; 14 days) produces inhibition of esophageal tumor growth in nude mice, reduces PCNA expression, and downregulates proteins in the PI3K/Akt-NF-κB signaling pathway[1].
Tenacissoside H (20-80 mg/kg; i.p.; daily; 5 consecutive days 30 minutes before operation) dose-dependently protects male C57BL/6 mice against cerebral ischemia-reperfusion injury, with the 80 mg/kg dose producing the most significant improvements in neurological function, reduction in brain damage, and modulation of inflammatory and oxidative stress pathways via the TrkB signaling axis[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Balb/c nude mice (male and female, 6 weeks old, 18-22 g, subcutaneous inoculation of EC9706 cells)[1]
Dosage: 100 mg/kg
Administration: i.p.; twice weekly; 14 days
Result: Reduced tumor volume.
Reduced PCNA positive cell ratio to 53.02%.
Downregulated PI3K, Akt, p-Akt and NF-κB protein expression.
Induced large areas of tumor necrosis.
Animal Model: C57BL/6 (male, 22-25 g, cerebral ischemia-reperfusion injury model via middle cerebral artery occlusion thread embolization with 2h ischemia followed by reperfusion)[2]
Dosage: 20 mg/kg; 40 mg/kg; 80 mg/kg
Administration: i.p.; daily; 5 consecutive days
Result: Reduced modified Neurological Severity Score (mNSS).
Reduced apoptotic cell and Caspase3-positive cells.
Reduced cerebral MDA, SOD, GSH-PX, BDNF levels.
Reduced TNF-α, IL-1β, IL-6 levels, increased IL-4, IL-10, TGF-β levels.
Reduced iNOS relative expression, increased Arg1 relative expression, reduced Iba1-positive microglia.
Increased Nrf2 relative expression, reduced p-NF-κB relative expression, increased TrkB relative expression, increased PPARγ relative expression.
Molecular Weight

794.97

Formula

C42H66O14
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

C[C@@]([C@@H]([C@@H](OC(C(C)CC)=O)[C@]1([H])[C@]23C)OC(C)=O)([C@@H]4C(C)=O)[C@]5(CC4)[C@@]1(CC[C@@]2([H])C[C@@H](O[C@@](O[C@H](C)[C@H]6O[C@@](O[C@H](C)[C@@H](O)[C@H]7OC)([H])[C@@H]7O)([H])C[C@H]6OC)CC3)O5
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (125.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.2579 mL 6.2895 mL 12.5791 mL
5 mM 0.2516 mL 1.2579 mL 2.5158 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: 5 mg/mL (6.29 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (3.14 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.89%

SDS (252 KB)

COA (256 KB) HNMR (417 KB) CNMR (396 KB) LCMS (90 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.2579 mL 6.2895 mL 12.5791 mL 31.4477 mL
5 mM 0.2516 mL 1.2579 mL 2.5158 mL 6.2895 mL
10 mM 0.1258 mL 0.6290 mL 1.2579 mL 3.1448 mL
15 mM 0.0839 mL 0.4193 mL 0.8386 mL 2.0965 mL
20 mM 0.0629 mL 0.3145 mL 0.6290 mL 1.5724 mL
25 mM 0.0503 mL 0.2516 mL 0.5032 mL 1.2579 mL
30 mM 0.0419 mL 0.2097 mL 0.4193 mL 1.0483 mL
40 mM 0.0314 mL 0.1572 mL 0.3145 mL 0.7862 mL
50 mM 0.0252 mL 0.1258 mL 0.2516 mL 0.6290 mL
60 mM 0.0210 mL 0.1048 mL 0.2097 mL 0.5241 mL
80 mM 0.0157 mL 0.0786 mL 0.1572 mL 0.3931 mL
100 mM 0.0126 mL 0.0629 mL 0.1258 mL 0.3145 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Tenacissoside H Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tenacissoside H191729-45-0Tenacissimoside CPI3KAktNF-κBApoptosisPhosphoinositide 3-kinasePKBProtein kinase BNuclear factor-κBNuclear factor-kappaBmale C57BL/6 micenecrosisapoptosisnude miceTrkB signaling pathwayesophageal cancerhuman esophageal carcinoma EC9706 cellcerebral ischemia/reperfusion-induced acute brain injurycell cycle arrestPI3K/Akt-NF-κB cascadeInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Tenacissoside H
Cat. No.:
HY-N0670
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.